Medicare Part D beneficiaries would see the largest percentage decrease in costs sharing for oncology drugs under the Part D redesign proposed in drug pricing legislation sponsored by Sens. Chuck Grassley, R-IA, and Ron Wyden, D-OR, according to a recent analysis by Manatt Health.
“Among the top 10 drug groups by gross Part D drug costs, the drug groups with the largest percentage decrease...







